Recombinant Human CDK8, His-tagged

• Cat.No.: CDK8-08H
• Product Overview: Recombinant Human Cyclin-Dependent Kinase 8 is expressed inE. colias a full-length protein fused to a proprietary 16-Kd tag (a 6xHis tag is located at the very N-terminal end). CDK8 is purified by proprietary chromatographic techniques.

Specification

• Cat. No.: CDK8-08H
• Description: CDK8 (cyclin-dependent kinase 8; protein kinase K35; CDK8 protein kinase; cell division protein kinase 8; K35) is a member of the cyclin-dependent protein kinase (CDK) family. CDK family members are highly similar to the gene products of Saccharomyces cerevisiae cdc28, and Schizosaccharomyces pombe cdc2, and are known to be important regulators of cell cycle progression. This kinase and its regulatory subunit cyclin C are components of the RNA polymerase II holoenzyme complex, which phosphorylates the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II. This kinase has also been shown to regulate transcription by targeting the CDK7/cyclin H subunits of the general transcription initiation factor IIH (TFIIH), thus providing a link between the "Mediator-like" protein complexes and the basal transcription machinery.
• Source: Escherichia Coli.
• Purity: Greater than 90% as determined by SDS-PAGE.
• Formulation: CDK8 is supplied at 0.1mg/ml in a buffer containing 25 mM HEPES, pH 7.9, 125mM KCI, 0.5% TX-100 and 50% glycerol.
• Application: CDK-8can be used directly as a positive control in Western blotting, ELISA, immunoprecipitation and other immunological experiments. The biological activity of this product has not yet been tested.
• Storage: Store at 4°C if entire vial will be used within 1-2 weeks. Store, frozen at -20°C for longer periods of time. Avoid multiple freeze-thaw cycles.

Gene Information

• Gene Name: CDK8 cyclin-dependent kinase 8 [ Homo sapiens ]
• Synonyms: cyclin-dependent kinase 8; K35; MGC126074; MGC126075; protein kinase K35; CDK8 protein kinase; cell division protein kinase 8; EC 2.7.11.22,EC 2.7.11.23; Protein kinase K35; CDK8; OTTHUMP00000018158; Mediator complex subunitCDK8; Mediator of RNA polymerase II transcription subunitCDK8
• Gene ID: 1024
• mRNA Refseq: NM_001260
• Protein Refseq: NP_001251
• MIM: 603184
• UniProt ID: P49336
• Chromosome Location: 13q12
• Pathway: Gene Expression
• Function: RNA polymerase II carboxy-terminal domain kinase activity; cyclin-dependent protein kinase activity; nucleotide binding; transferase activity; protein binding; ATP binding

Reviews

03/05/2020

The CDK8 protein stands as a remarkable solution that exemplifies exceptional quality and meets all my experimental requirements.

08/03/2019

I am confident that the CDK8 protein will unlock vital insights into cellular processes, propelling my scientific investigations to new heights.

10/01/2017

Its impressive purity and functional characteristics make it an ideal choice for my research endeavors, ensuring reliable and impactful results.

Q&As

Is CDK8 exclusively associated with cancer, or does it have physiological roles in normal cellular functions?

CDK8 plays essential roles in normal cellular functions, including development and tissue homeostasis. Its dysregulation, however, is implicated in cancer.

Can CDK8 inhibitors be used in combination with other cancer treatments, and if so, what are the potential benefits?

Combination therapies involving CDK8 inhibitors are being explored to enhance treatment outcomes and reduce the likelihood of resistance, providing a more comprehensive approach to cancer management.

How does CDK8 inhibition affect the cell cycle, and why is this significant in cancer therapy?

CDK8 inhibition can disrupt the cell cycle, slowing down or halting the uncontrolled cell division characteristic of cancer cells, making it a potential therapeutic strategy.

How does CDK8 influence the immune response in the tumor microenvironment?

CDK8 can modulate the expression of genes involved in immune response. Understanding its role in the tumor microenvironment may lead to novel immunotherapeutic strategies.

Are there ongoing clinical trials investigating the efficacy of CDK8 inhibitors in cancer patients?

Yes, several clinical trials are underway to assess the safety and effectiveness of CDK8 inhibitors as a targeted therapy for different types of cancer.